Phibro Animal Health Corporation (PAHC)
Pretax margin
Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | ||
---|---|---|---|---|---|---|
Earnings before tax but after interest (EBT) | US$ in thousands | 10,916 | 54,071 | 72,327 | 66,468 | 55,512 |
Revenue | US$ in thousands | 993,816 | 960,113 | 935,602 | 833,350 | 800,354 |
Pretax margin | 1.10% | 5.63% | 7.73% | 7.98% | 6.94% |
June 30, 2024 calculation
Pretax margin = EBT ÷ Revenue
= $10,916K ÷ $993,816K
= 1.10%
The pretax margin of Phibro Animal Health Corporation has shown a decreasing trend over the past five years, declining from 7.98% in June 2021 to 1.10% in June 2024. This indicates that the company's profitability before taxes has been eroding. The significant drop in pretax margin suggests that the company's ability to generate profits from its operations has weakened over the period under review. Further investigation into the factors driving this decline in profitability would be necessary to understand the challenges facing Phibro Animal Health Corporation.
Peer comparison
Jun 30, 2024
Company name
Symbol
Pretax margin
Phibro Animal Health Corporation
PAHC
1.10%
Abbott Laboratories
ABT
16.90%
AbbVie Inc
ABBV
11.49%
Alkermes Plc
ALKS
15.74%
Amphastar P
AMPH
26.28%
ANI Pharmaceuticals Inc
ANIP
4.37%
Arcus Biosciences Inc
RCUS
-257.26%
Biomarin Pharmaceutical Inc
BMRN
7.94%
Bristol-Myers Squibb Company
BMY
18.72%
Catalent Inc
CTLT
-23.44%
Catalyst Pharmaceuticals Inc
CPRX
23.73%